SMN1 and proximal spinal muscular atrophy: These elements collectively form a biomarker system for assessing protective effects against SMA and provide new targets for screening asymptomatic individuals with SMN1 deletion, as well as for elucidating mechanisms underlying aberrant PLS3 expression [149].